What is Thirona?
Thirona is at the forefront of leveraging artificial intelligence for respiratory health, offering its proprietary LungQ platform. This advanced technology provides detailed quantitative analysis of thoracic CT scans, empowering clinicians with critical insights for the detection, monitoring, and management of pulmonary diseases such as severe asthma, bronchiectasis, COPD, and cystic fibrosis. The company's solutions are instrumental in drug development and the planning of lung interventions, aiming to enhance precision medicine within the field of respiratory care. Thirona's commitment to a strong scientific foundation and cutting-edge technology positions it as a key player in supporting clinical trials and delivering high-performance results in lung disease assessment.
How much funding has Thirona raised?
Thirona has raised a total of $7.9M across 2 funding rounds:
Grant
$2.7M
Other Financing Round
$5.2M
Grant (2023): $2.7M with participation from The European Innovation Council
Other Financing Round (2023): $5.2M led by Borski Fund and Heran Partners
Key Investors in Thirona
Borski Fund
Borski Fund is a venture capital firm that champions investments in companies led by women or those serving women's needs, aiming to address the gender gap in investment by supporting female entrepreneurs and businesses.
Heran Partners
Heran Partners is a venture capital investor based in Belgium, concentrating on transformative impacts within the healthcare and life sciences sectors by backing innovative companies with strong scientific and entrepreneurial foundations.
The European Innovation Council
The European Innovation Council is an entity operating within the Colleges & Universities sector, focused on fostering innovation and supporting groundbreaking projects.
What's next for Thirona?
With the recent major strategic investment and substantial overall capital, Thirona is poised for accelerated growth and further innovation in AI-driven lung diagnostics. This financing is expected to fuel the expansion of its LungQ platform's capabilities, potentially broadening its application across a wider spectrum of respiratory conditions and enhancing its utility in global clinical trials. The strategic nature of the recent backing suggests a focus on deepening market penetration, forging key partnerships within the pharmaceutical and healthcare sectors, and potentially scaling its operations to meet the increasing demand for advanced, data-driven solutions in precision medicine for lung health.
See full Thirona company page
